Vir Biotechnology: Catalysts Ahead In Hepatitis And Oncology
Source: SeekingAlpha
2025-03-04 11:49:47 ET
Summary
- Vir Biotechnology's T-cell engagers have potential in oncology and showed promise with initial data in January 2025, but the stock's rally has since faded.
- Additional data from the MARCH Part B trial for chronic hepatitis B is expected in Q2'25, but the company won't develop further there without a partner.
- VIR hasn't provided an exact timeline for the next update from its T-cell engager work, although the company plans to initiate work with a third T-cell engager in 2025.
...
Read the full article on Seeking Alpha
For further details see:
Vir Biotechnology: Catalysts Ahead In Hepatitis And Oncology
Janux Therapeutics Inc.
NASDAQ: JANX
JANX Trading
-0.68% G/L:
$14.64 Last:
514,387 Volume:
$14.74 Open:
JANX Latest News
May 07, 2026 04:01:00 pm
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
April 27, 2026 04:01:00 pm
Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development
April 16, 2026 04:01:00 pm
Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014
JANX Stock Data
$789,139,228
45,531,890
1.75%
55
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
